TY - JOUR
T1 - Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium
AU - International Guideline Harmonization Group ototoxicity group
AU - Clemens, Eva
AU - van den Heuvel-Eibrink, Marry M.
AU - Mulder, Renée L.
AU - Kremer, Leontien C. M.
AU - Hudson, Melissa M.
AU - Skinner, Roderick
AU - Constine, Louis S.
AU - Bass, Johnnie K.
AU - Kuehni, Claudia E.
AU - Langer, Thorsten
AU - van Dalen, Elvira C.
AU - Bardi, Edith
AU - Bonne, Nicolas-Xavier
AU - Brock, Penelope R.
AU - Brooks, Beth
AU - Carleton, Bruce
AU - Caron, Eric
AU - Chang, Kay W.
AU - Johnston, Karen
AU - Knight, Kristin
AU - Nathan, Paul C.
AU - Orgel, Etan
AU - Prasad, Pinki K.
AU - Rottenberg, Jan
AU - Scheinemann, Katrin
AU - de Vries, Andrica C. H.
AU - Walwyn, Thomas
AU - Weiss, Annette
AU - am Zehnhoff-Dinnesen, Antoinette
AU - Cohn, Richard J.
AU - Landier, Wendy
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
AB - Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems—such as speech and language, social–emotional development, and learning difficulties—for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
UR - http://www.scopus.com/inward/record.url?scp=85059341149&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S1470-2045(18)30858-1
DO - https://doi.org/10.1016/S1470-2045(18)30858-1
M3 - Review article
SN - 1470-2045
VL - 20
SP - e29-e41
JO - lancet oncology
JF - lancet oncology
IS - 1
ER -